Core Insights - Eledon Pharmaceuticals reported significant progress in its clinical trials and financial position, particularly with the Phase 2 BESTOW trial for tegoprubart in kidney transplantation [2][3] - The company completed an oversubscribed private placement raising $50 million, ensuring liquidity through December 2025 [1][7] Clinical Developments - The Phase 2 BESTOW trial has enrolled 80 participants, with expectations to complete enrollment by the end of 2024 [3][4] - Updated data from a Phase 1b trial indicated that tegoprubart was generally safe and well-tolerated, with a mean estimated glomerular filtration rate (eGFR) of 70.5 mL/min/1.73m² after day 30 post-transplant [3] - Two participants in the Phase 1b trial maintained eGFRs above 90 mL/min/1.73m² at one year post-transplant [3] Financial Overview - The company ended Q2 2024 with approximately $83.6 million in cash and cash equivalents, bolstered by the recent private placement [7] - A reclassification of certain common stock warrants as liabilities is expected, but this is a non-cash adjustment and will not impact the company's cash position [5][7] Future Milestones - Eledon anticipates completing enrollment in the Phase 2 BESTOW trial by the end of 2024 and plans to report updated interim clinical data by mid-2025 [4]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Delaware 001-36620 20-1000967 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value ELDN Nasdaq Global Market FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 Eledon ...

IRVINE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ: ELDN) today announced that it has enrolled the 80th participant in its ongoing Phase 2 BESTOW trial assessing tegoprubart for the prevention of rejection in kidney transplantation. "As of this week, we have already enrolled two-thirds of the projected study participants across sites in the United States, Europe and Latin America," said David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon. "We are g ...

Eledon is currently conducting a Phase 2 trial (BESTOW; NCT05983770), a Phase 1b trial (NCT05027906), and a long-term safety and efficacy extension study (NCT06126380) to evaluate tegoprubart for the prevention of organ rejection in patients receiving a kidney transplant. "As of this week, we have already enrolled two-thirds of the projected study participants across sites in the United States, Europe and Latin America," said David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon. "We are grateful ...

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company's lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an att ...

分组1: Tilray Brands - The cannabis industry is experiencing significant interest following the DEA's proposal to reschedule marijuana to a Schedule Three controlled substance, positioning Tilray Brands to benefit from potential U.S. market expansion [3][6] - Tilray has reported a 30% year-over-year revenue increase, with positive sales across its cannabis, distribution, and alcohol segments [4] - Despite facing challenges, including a bankruptcy in its portfolio affecting U.S. expansion plans, Tilray is reassessing its strategy and remains optimistic about future opportunities [5][6] 分组2: Rigel Pharmaceuticals - Rigel Pharmaceuticals is focused on developing treatments for hematologic disorders and cancer, with two FDA-approved products: Tavalisse for chronic immune thrombocytopenia and Rezlidhia for acute myeloid leukemia [8][9] - Tavalisse generated $21.1 million in net product sales last quarter, while Rezlidhia contributed $4.9 million, indicating a solid revenue stream [9] - The company has reduced its net loss by $5.3 million compared to the previous year and is actively sharing promising data from its pipeline, enhancing investor confidence [10][11] 分组3: Eledon Pharmaceuticals - Eledon Pharmaceuticals is dedicated to improving organ transplant success rates and is developing Tegoprubart to prevent rejection in kidney transplant patients [13][14] - The company reported a flat net loss year-over-year but secured $50 million in gross proceeds from private placement financing, supporting ongoing research and development [15] - Eledon is nearing the completion of patient enrollment for phase 2 trials of Tegoprubart, indicating potential for significant advancements in the near future [14][15] 分组4: Market Outlook - The three highlighted penny stocks—Tilray Brands, Rigel Pharmaceuticals, and Eledon Pharmaceuticals—are positioned for growth due to their innovative products and favorable market conditions, despite inherent risks [18]

Core Insights - Eledon Pharmaceuticals presented updated data from its ongoing Phase 1b trial of tegoprubart, showing promising safety and efficacy in preventing organ rejection in kidney transplant patients [1][2][3] Group 1: Clinical Trial Results - The overall mean estimated glomerular filtration rate (eGFR) after day 30 post-transplant was reported at 70.5 mL/min/1.73m², with mean eGFR above 60 mL/min/1.73m² at all reported time points [1][2] - Historical studies indicate that standard calcineurin inhibitor-based immunosuppression typically results in mean eGFRs of approximately 50 mL/min/1.73m² during the first year post-transplant, while tegoprubart showed mean eGFRs above 90 mL/min/1.73m² in two participants after one year [2][3] Group 2: Safety Profile - Tegoprubart demonstrated a generally safe and well-tolerated profile, with no cases of hyperglycemia, new onset diabetes, or tremor reported, which are common side effects of standard immunosuppression therapies [3] - Three subjects discontinued the study due to hair loss and fatigue, viral infection, and rejection, but there were no cases of graft loss or death [3] Group 3: Future Developments - Eledon is conducting a Phase 1b trial, a Phase 2 trial (BESTOW), and a long-term safety and efficacy extension study to further evaluate tegoprubart for kidney transplant patients [4][5] - The company anticipates completing enrollment in the Phase 2 BESTOW trial by the end of the year [2]

Core Insights - Eledon Pharmaceuticals presented updated data on tegoprubart, an anti-CD40L antibody, at the American Transplant Congress, indicating its potential for preventing organ rejection in kidney transplant patients [1][2] - The ongoing Phase 1b trial shows promising results, with an overall mean estimated glomerular filtration rate (eGFR) of 70.5 mL/min/1.73m² after day 30 post-transplant, significantly higher than the typical 50 mL/min/1.73m² reported with standard calcineurin inhibitor therapies [2][3] Company Overview - Eledon Pharmaceuticals is a clinical-stage biotechnology company focused on developing immune-modulating therapies for life-threatening conditions, with tegoprubart as its lead investigational product [5] - The company is conducting multiple clinical trials, including a Phase 1b trial, a Phase 2 trial (BESTOW), and a long-term safety and efficacy extension study [4] Clinical Trial Results - Data from 13 participants in the Phase 1b trial indicate that tegoprubart is generally safe and well tolerated, with no cases of hyperglycemia, new onset diabetes, or tremor reported [3] - Two participants who completed 12 months on therapy post-transplant demonstrated mean eGFRs above 90 mL/min/1.73m², further supporting the drug's efficacy [2] Future Plans - The company aims to continue accruing data from the ongoing Phase 1b and open-label extension studies while also enrolling participants in the Phase 2 BESTOW trial, with completion expected by the end of the year [2]

In simple terms, during a downtrend, with bears having absolute control, a stock usually opens lower compared to the previous day's close, and again closes lower. On the day the hammer pattern is formed, maintaining the downtrend, the stock makes a new low. However, after eventually finding support at the low of the day, some amount of buying interest emerges, pushing the stock up to close the session near or slightly above its opening price. When it occurs at the bottom of a downtrend, this pattern signals ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades. While many investors like to look for momen ...